Wellington Management Group LLP Grows Stake in Celldex Therapeutics, Inc. $CLDX

Wellington Management Group LLP lifted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 11.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,543,671 shares of the biopharmaceutical company’s stock after purchasing an additional 983,195 shares during the quarter. Wellington Management Group LLP owned about 0.12% of Celldex Therapeutics worth $355,120,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in CLDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Celldex Therapeutics by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after buying an additional 680 shares in the last quarter. Millennium Management LLC increased its stake in Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock worth $7,259,000 after acquiring an additional 306,330 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock valued at $2,383,000 after acquiring an additional 14,979 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of Celldex Therapeutics during the second quarter worth about $347,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on CLDX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Friday, July 17th. Morgan Stanley raised their price objective on shares of Celldex Therapeutics from $40.00 to $46.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Wells Fargo & Company lifted their price objective on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Canaccord Genuity Group reduced their target price on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Finally, UBS Group lifted their price target on Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.08.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock opened at $39.12 on Monday. The stock has a market capitalization of $3.07 billion, a P/E ratio of -8.99 and a beta of 0.87. Celldex Therapeutics, Inc. has a one year low of $21.71 and a one year high of $45.14. The business’s 50 day simple moving average is $38.51 and its two-hundred day simple moving average is $33.33.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.12. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.73 million. Sell-side analysts expect that Celldex Therapeutics, Inc. will post -4.13 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.